Early Genetic Divergence of High-Grade Carcinomas Originating from Low-Grade Serous Ovarian Neoplasms von Chui, M. Herman, Song, Qianqian, Zhu, Jiarun, Jiao, Yuchen, Wang, Brant, Wang, Yeh, Wang, Tian-Li, Vang, Russell, Shih, Ie-Ming

Volltext

The highs and lows of serous ovarian cancer von Grisham, Rachel N., Manning‐Geist, Beryl L., Chui, M. Herman

Volltext

Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma von Chui, M. Herman, Momeni Boroujeni, Amir, Mandelker, Diana, Ladanyi, Marc, Soslow, Robert A.

Volltext

Beyond the estrogen receptor: In search of predictive biomarkers for low‐grade serous ovarian cancer von Grisham, Rachel N., Manning‐Geist, Beryl L., Chui, M. Herman

Volltext

Mullerian adenosarcoma: clinicopathologic and molecular characterization highlighting recurrent BAP1 loss and distinctive features of high-grade tumors von Momeni Boroujeni, Amir, Kertowidjojo, Elizabeth, Wu, Xinyu, Soslow, Robert A., Chiang, Sarah, Da Silva, Edaise M., Weigelt, Britta, Chui, M. Herman

Volltext

Advancements in Low-Grade Serous Carcinoma of the Ovary and Peritoneum von Grisham, Rachel N., Chui, M. Herman

Volltext

Chromosomal Instability and mTORC1 Activation through PTEN Loss Contribute to Proteotoxic Stress in Ovarian Carcinoma von Chui, M Herman, Doodnauth, Sasha A, Erdmann, Natalie, Tiedemann, Rodger E, Sircoulomb, Fabrice, Drapkin, Ronny, Shaw, Patricia, Rottapel, Robert

Volltext

Endometriosis: benign, malignant, or something in between? von Chui, M Herman, Wang, Tian-Li, Shih, Ie-Ming

Volltext

Correction: BRAFV600E -mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma von Chui, M. Herman, Kjaer, Susanne K., Frederiksen, Kirsten, Hannibal, Charlotte G., Wang, Tian-Li, Vang, Russell, Shih, Ie-Ming

Volltext

BRAFV600E -mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma von Chui, M. Herman, Kjaer, Susanne K., Frederiksen, Kirsten, Hannibal, Charlotte G., Wang, Tian-Li, Vang, Russell, Shih, Ie-Ming

Volltext

Loss of ALDH1A1 expression is an early event in the pathogenesis of ovarian high-grade serous carcinoma von Chui, M Herman, Wang, Yihong, Wu, Ren-Chin, Seidman, Jeffrey, Kurman, Robert J, Wang, Tian-Li, Shih, Ie-Ming

Volltext

Platelet factors attenuate inflammation and rescue cognition in ageing von Schroer, Adam B., Ventura, Patrick B., Sucharov, Juliana, Misra, Rhea, Chui, M. K. Kirsten, Bieri, Gregor, Horowitz, Alana M., Smith, Lucas K., Encabo, Katriel, Tenggara, Imelda, Couthouis, Julien, Gross, Joshua D., Chan, June M., Luke, Anthony, Villeda, Saul A.

Volltext

Primary Marginal Zone Lymphoma of the Subcutis Associated With Panniculitis and Fat Necrosis von Chui, M. Herman, Kukreti, Vishal, Wei, Cuihong, Delabie, Jan

Volltext

Chemotherapy response in low‐grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapies von Manning‐Geist, Beryl L., Kahn, Ryan M., Nemirovsky, David, Girshman, Jeffrey, Laibangyang, Anya, Gordhandas, Sushmita, Iasonos, Alexia, Chui, M. Herman, Long Roche, Kara, Zivanovic, Oliver, Chi, Dennis S., Aghajanian, Carol, Grisham, Rachel N.

Volltext

Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities von Manning-Geist, Beryl L., Sullivan, Mackenzie W., Zhou, Qin, Iasonos, Alexia, Selenica, Pier, Stallworth, Chrystal, Liu, Ying L., Long Roche, Kara, Gordhandas, Sushmita, Aghajanian, Carol, Chi, Dennis, O'Cearbhaill, Róisín, Grisham, Rachel N., Chui, M. Herman

Volltext

A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2) von Lumish, Melissa, Chui, M. Herman, Zhou, Qin, Iasonos, Alexia, Sarasohn, Debra, Cohen, Seth, Friedman, Claire, Grisham, Rachel, Konner, Jason, Kyi, Chrisann, Rubinstein, Maria, Troso-Sandoval, Tiffany, Aghajanian, Carol, Makker, Vicky

Volltext

Decreased HER2 expression in endometrial cancer following anti-HER2 therapy von Chui, M Herman, Brown, David N, Da Cruz Paula, Arnaud, da Silva, Edaise M, Momeni-Boroujeni, Amir, Reis-Filho, Jorge S, Zhang, Yanming, Makker, Vicky, Ellenson, Lora Hedrick, Weigelt, Britta

Volltext

TROP2 as a novel target in uterine carcinosarcoma organoid models von Moufarrij, Sara, Dopeso, Higinio, Green, Hunter, Gill, Kaitlyn, Brown, David, Zammarrelli, William, Varice, Nancy, Wu, Michelle, Paula, Arnaud Da Cruz, de Oliveira, Thais Basili, Abu-Rustum, Nadeem, Aghajanian, Carol, Ellenson, Lora, Chui, M. Herman, Weigelt, Britta

Volltext

Sensitivity of HER2-low uterine carcinosarcoma organoids to the antibody-drug conjugate, trastuzumab deruxtecan von Moufarrij, Sara, Dopeso, Higinio, Green, Hunter, Gill, Kaitlyn, Brown, David, Zammarrelli, William, Varice, Nancy, Wu, Michelle, Paula, Arnaud Da Cruz, de Oliveira, Thais Basili, Abu-Rustum, Nadeem, Aghajanian, Carol, Ellenson, Lora, Chui, M. Herman, Weigelt, Britta

Volltext

HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer von Shen, Sherry, Ma, Weining, Brown, David, Da Cruz Paula, Arnaud, Zhou, Qin, Iaosonos, Alexia, Tessier-Cloutier, Basile, Ross, Dara S., Troso-Sandoval, Tiffany, Reis-Filho, Jorge S., Abu-Rustum, Nadeem, Zhang, Yanming, Ellenson, Lora H., Weigelt, Britta, Makker, Vicky, Chui, M. Herman

Volltext